Eagle Asset Management Inc. Purchases 234,305 Shares of Eli Lilly And Co (NYSE:LLY)
Eagle Asset Management Inc. grew its stake in Eli Lilly And Co (NYSE:LLY) by 1,392.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 251,136 shares of the company’s stock after acquiring an additional 234,305 shares during the period. Eagle Asset Management Inc.’s holdings in Eli Lilly And Co were worth $28,084,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Selective Wealth Management Inc. bought a new position in shares of Eli Lilly And Co in the third quarter worth about $25,000. Enterprise Trust & Investment Co bought a new position in shares of Eli Lilly And Co in the third quarter worth about $27,000. Garrett Wealth Advisory Group LLC bought a new position in shares of Eli Lilly And Co in the third quarter worth about $29,000. Candriam Luxembourg S.C.A. raised its stake in shares of Eli Lilly And Co by 47.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock worth $30,000 after acquiring an additional 87,250 shares during the last quarter. Finally, Prestige Wealth Management Group LLC bought a new position in shares of Eli Lilly And Co in the second quarter worth about $34,000. 77.22% of the stock is owned by institutional investors.
A number of equities analysts have weighed in on the stock. Bank of America assumed coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They issued a “buy” rating and a $133.00 target price for the company. UBS Group dropped their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday, October 17th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $130.03.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the previous year, the company earned $1.39 EPS. Eli Lilly And Co’s revenue was up 3.2% on a year-over-year basis. As a group, research analysts predict that Eli Lilly And Co will post 5.78 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.27%. The ex-dividend date of this dividend is Thursday, November 14th. Eli Lilly And Co’s dividend payout ratio is 46.49%.
In other news, SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the completion of the sale, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the sale, the senior vice president now owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. In the last quarter, insiders have bought 8,405 shares of company stock valued at $909,004 and have sold 614,373 shares valued at $70,546,895. 0.11% of the stock is owned by insiders.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Are we seeing the beginning of a new bubble?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.